Nephrotoxicity is a major hazard complicating the use of platinum based drugs (PBD), which can hinder using higher doses protocols to maximize the therapeutic gain. Shortage of serum creatinine level as an accurate biomarker for acute kidney injuries (AKI) necessitates searching for novel biomarkers with better sensitivity and specificity in patients on PBD.
In a prospective cohort design, 132 patients receiving PBD were selected for the study. AKI was diagnosed by continuous follow up of serum creatinine level according to Kidney Disease: Improving Global Outcomes (KDIGO) guidelines 2012. Serum creatinine and urinary biomarkers (KIM-1, NGAL and cystatin C) was measured in the day of treatment and for 3 days after PBD cycle.
AKI occurred in 35 patients (26.52% of patients). KIM-1, Cystatin C, and NGAL showed significant increase in samples collected in the day of AKI in comparison to their corresponding basal levels (P < 0.0001). In addition, significant increase in urinary levels of the biomarkers in samples collected 1 day before AKI in comparison to their basal levels (P < 0.0001, P < 0.0001, and P = 0.013 for KIM-1, NGAL and Cystatin C respectively). Furthermore KIM-1 data showed a significant increase 2 days before serum creatinine rise in comparison to the corresponding KIM-1 levels in patients who developed AKI (P = 0.001).
Urinary KIM-1, Cystatin C and NGAL can predict PBD induced AKI in earlier stages than serum createnine. KIM-1 is the most sensitive biomarker for early detection of AKI in patients receiving PBD.
Berl T. American Society of Nephrology renal research report. J Am Soc Nephrol. 2005;
Shao X, Tian L, Xu W, Zhang Z, Wang C, Qi C, et al. Diagnostic value of urinary kidney injury molecule 1 for acute kidney injury: a meta-analysis. PLoS One. 2014;9(1):e84131. https://doi.org/10.1371/journal.pone.0084131. CrossRefPubMedPubMedCentral
Ali I, A Wani W, Saleem K, Haque A. Platinum compounds: a hope for future cancer chemotherapy. Antibiotiki (Mosc). 2013;13(2):296–306.
Labaye J, Sarret D, Duvic C, Hérody M, Didelot F, Nédélec G, Noël LH. Renal toxicity of oxaliplatin. Nephro Dial Transplant. 2005;20(6):1275–6. CrossRef
Yaghobi Joybari A, Sarbaz S, Azadeh P, Mirafsharieh SA, Rahbari A, Farasatinasab M, Mokhtari M. Oxaliplatin-induced renal tubular vacuolization. Ann Pharmacother. 2014;48(6):796–800. CrossRef
Isnard-Bagnis C, Launay-Vacher V, Karie S, Deray G. Anticancer drugs. In: Clinical Nephrotoxins Renal Injury from Drug and Chemicals, edited by De Broe M, Porter G, Bennett W, Deray G, 3rd Ed., New York, Springer Scientific, 511–535 2008.
Muggia FM, Braly PS, Brady MF, Sutton G, Niemann TH, Lentz SL, Alvarez RD, Kucera PR, Small JM. Phase III randomized study of cisplatin versus paclitaxel versus cisplatin and paclitaxel in patients with suboptimal stage III or IV ovarian cancer: a gynecologic oncology group study. J Clin Oncol. 2000;18(1):106. CrossRefPubMed
Chaturvedi, Shalini, Takeisha Farmer, and Gordon F. Kapke. “Assay validation for KIM-1: human urinary renal dysfunction biomarker.” Int J Biol Sci 5.2 (2009): 128–134. Print.
KDIGO Clinical Practice Guideline for Acute Kidney Injury Kidney International Supplements (2012) 2;1 https://doi.org/10.1038/kisup.2012.1
Faig J, Haughton M, Taylor RC, D’Agostino RB Jr, Whelen MJ, Rodriguez KA, Bonomi M, Murea M, Porosnicu M. Retrospective analysis of cisplatin nephrotoxicity in patients with head and neck Cancer receiving outpatient treatment with concurrent high-dose cisplatin and radiotherapy. Am J Clin Oncol. 2017.
Gaspari F, Cravedi P, Mandalà M, Perico N, De Leon FR, Stucchi N, Ferrari S, Labianca R, Remuzzi G, Ruggenenti P. Predicting cisplatin-induced acute kidney injury by urinary neutrophil gelatinase-associated lipocalin excretion: a pilot prospective case-control study. Nephron Clin Pract. 2010;115(2):c154–60. CrossRefPubMed
- Urinary biomarkers for early detection of platinum based drugs induced nephrotoxicity
Ahmed Abd El Wahab
Maysaa El Sayed Zaki
- BioMed Central
Neu im Fachgebiet Innere Medizin
Meistgelesene Bücher aus der Inneren Medizin
Mail Icon II